Job Description
Amarin Corporation plc (“Amarin”) is a rapidly growing pharmaceutical company developing and selling therapeutics to improve cardiovascular health. Amarin, a publicly traded company (NASDAQ: AMRN) with approximately 900 employees, is headquartered in Dublin, Ireland and has its US operations (Amarin Pharma Inc.) based in Central New Jersey. Amarin has successfully developed, registered and launched VASCEPA® in the U.S. market with a network of third-party companies aligned with Amarin to advance commercialization of VASCEPA® globally. In the U.S., VASCEPA® was launched in 2013 for its initial indication of as a treatment of Very High Triglycerides (i.e. patients with TG levels ≥ 500mg/dL).
In November 2018, unprecedented clinical results were announced from a landmark global cardiovascular outcomes study in which VASCEPA®demonstrated a significantly lower risk of cardiovascular events beyond the current standard of care for cholesterol management. This study was recognized as a top clinical result in 2018 by The New England Journal of Medicine. Amarin recently announced plans to increase the size of the U.S. sales force from 400 to 800 sales representatives. Amarin anticipates accelerated revenue growth from VASCEPA® based on the unprecedented results recently announced from its outcomes study called REDUCE-IT. In December 2019, Amarin received approval from the FDA on an expanded label for VASCEPA® to reflect the results of the REDUCE-IT study. Amarin is a science driven company focused on improving patient care. It is truly an exciting time to join the Amarin team.
THERAPEUTICS TO IMPROVE CARDIOVASCULAR HEALTH
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription.
Development of Vascepa leveraged Amarin’s extensive experience in lipid sciences and the potential therapeutic benefits of polyunsaturated fatty acids. Such development challenged previously established norms to create a potent, yet safe, targeted single ingredient product in contrast to prior generation omega-3 mixtures and other prescription drugs. The use of Vascepa is now supported by over 40 granted patents and by FDA designation in 2015 of Vascepa’s active ingredient as a New Chemical Entity. This means that no prior FDA-approved drug had the active ingredient contained in Vascepa. Also, no prior drug with icosapent ethyl was ever characterized for FDA review and approved by the FDA to treat or prevent a medical condition.
